Arecor Therapeutics (LON:AREC) Share Price Breaks Above Fifty Day Moving Average – Time to Sell?

Arecor Therapeutics plc (LON:AREC) shares passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of GBX 80.58 and traded as high as GBX 81.50. Arecor Therapeutics shares last traded at GBX 81.50, with a volume of 2,750 shares.

Arecor Therapeutics Stock Up 2.6%

The stock has a market cap of £36.24 million, a price-to-earnings ratio of 80.00 and a beta of -0.18. The company has a quick ratio of 6.24, a current ratio of 4.29 and a debt-to-equity ratio of 1.55. The stock has a fifty day moving average of GBX 80.80 and a two-hundred day moving average of GBX 70.95.

Arecor Therapeutics (LON:AREC) last posted its quarterly earnings results on Thursday, October 1st. The company reported GBX (8) earnings per share (EPS) for the quarter. Arecor Therapeutics had a negative net margin of 200.00% and a positive return on equity of 3.75%. As a group, analysts predict that Arecor Therapeutics plc will post -0.35 EPS for the current fiscal year.

Arecor Therapeutics Company Profile

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases. Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.